Stifel Financial
AMRI

Stifel Financial’s Albany Molecular Research Inc AMRI Stock Holding History

Stifel Financial’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-13,300
Closed -$185K – 2676
2017
Q1 		$185K Buy
+13,300
New +$218K ﹤0.01% 2349

Other funds holding AMRI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
American Capital Management New York $1.86B AUM 20.23% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CCM
Chicago Capital Management Chicago, Illinois $121M AUM 74.36% 1-Year Est. Return
EWM
Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return

Stifel Financial's AMRI Position: Q2 2017 in Review

Stifel Financial sold out of Albany Molecular Research Inc (AMRI) in Q2 2017, closing a stake of 13,300 shares — an estimated $185K sold.

Stifel Financial first reported a position in AMRI in Q1 2017 and held it in 1 quarter. The position peaked at $185K in Q1 2017. 136 funds tracked by Wall St. Rank hold AMRI as of Q2 2017.

  • Stifel Financial reported no remaining Albany Molecular Research Inc position as of Q2 2017 after selling out during the quarter.
  • Stifel Financial sold 13,300 Albany Molecular Research Inc shares in Q2 2017, an estimated $185K.
  • Stifel Financial first reported a position in Albany Molecular Research Inc in Q1 2017 and held it in 1 quarter.
  • Stifel Financial's Albany Molecular Research Inc position peaked at $185K in Q1 2017.
  • 136 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q2 2017.

Based on Stifel Financial's 13F filing for Q2 2017, filed 14 Aug 2017.